Literature DB >> 28625384

Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy.

Alessandro Paoletti Perini1, Valentina Kutyifa2, Peter Veazie3, James P Daubert4, Claudio Schuger5, Wojciech Zareba3, Scott McNitt3, Spencer Rosero3, Christine Tompkins3, Luigi Padeletti6, Arthur J Moss3.   

Abstract

Effects of implantable cardioverter/defibrillator (ICD) shocks and antitachycardia pacing (ATP) on anxiety and quality of life (QoL) in ICD patients are poorly understood.
METHODS: We evaluated changes in QoL from baseline to 9-month follow-up using the EQ-5D questionnaire in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) (n=1,268). We assessed anxiety levels using the Florida Shock Anxiety Scale (1-10 score) in patients with appropriate or inappropriate shocks or ATP compared to those with no ICD therapy during the first 9 months postimplant. The analysis was stratified by number of ATP or shocks (0-1 vs ≥2) and adjusted for covariates.
RESULTS: In MADIT-RIT, 15 patients (1%) had ≥2 appropriate shocks, 38 (3%) had ≥2 appropriate ATPs. Two or more inappropriate shocks were delivered in 16 patients (1%); ≥2 inappropriate ATPs, in 70. In multivariable analysis, patients with ≥2 appropriate shocks had higher levels of shock-related anxiety than those with ≤1 appropriate shock (P<.01). Furthermore, ≥2 inappropriate shocks produced more anxiety than ≤1 inappropriate shock (P=.005). Consistently, ≥2 appropriate ATPs resulted in more anxiety than ≤1 (P=.028), whereas the number of inappropriate ATPs showed no association with anxiety levels (P=.997). However, there was no association between QoL and appropriate or inappropriate ATP/shock (all P values > .05).
CONCLUSIONS: In MADIT-RIT, ≥2 appropriate or inappropriate ICD shocks and ≥2 appropriate ATPs are associated with more anxiety at 9-month follow-up despite no significant changes in the assessment of global QoL by the EQ-5D questionnaire. Innovative ICD programming reducing inappropriate therapies may help deal with patient concerns about the device.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28625384     DOI: 10.1016/j.ahj.2017.03.009

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

Review 1.  Electromagnetic interference between implantable cardiac devices and continuous-flow left ventricular assist devices: a review.

Authors:  Jonathan S Gordon; Elizabeth J Maynes; Thomas J O'Malley; Behzad B Pavri; Vakhtang Tchantchaleishvili
Journal:  J Interv Card Electrophysiol       Date:  2021-01-12       Impact factor: 1.900

2.  Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial.

Authors:  Arwa Younis; Ilan Goldenberg; Shamroz Farooq; Hagai Yavin; James Daubert; Merritt Raitt; Alexander Mazur; David T Huang; Brent L Mitchell; Mayer R Rashtian; Stephen Winters; Margot Vloka; Mehmet Aktas; Matthew A Bernabei; Christopher A Beck; Scott McNitt; Wojciech Zareba
Journal:  JACC Clin Electrophysiol       Date:  2022-04-27

3.  Benefits of support groups for patients living with implantable cardioverter defibrillators: a mixed-methods systematic review and meta-analysis.

Authors:  Katie H Sanders; Panagiota Anna Chousou; Kathryn Carver; Peter J Pugh; Hans Degens; May Azzawi
Journal:  Open Heart       Date:  2022-10

4.  Non-invasive Cardiac Radiation for Ablation of Ventricular Tachycardia: a New Therapeutic Paradigm in Electrophysiology.

Authors:  Eun-Jeong Kim; Giovanni Davogustto; William G Stevenson; Roy M John
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-03

5.  Aerobic Exercise Effects on Quality of Life and Psychological Distress After an Implantable Cardioverter Defibrillator.

Authors:  Cynthia M Dougherty; Robert L Burr; Peter J Kudenchuk; Robb W Glenny
Journal:  J Cardiopulm Rehabil Prev       Date:  2020-03       Impact factor: 3.646

6.  Survival After Implantable Cardioverter-Defibrillator Shocks.

Authors:  Mehmet K Aktaş; Arwa Younis; Wojciech Zareba; Valentina Kutyifa; Helmut Klein; James P Daubert; Mark Estes; Scott McNitt; Bronislava Polonsky; Ilan Goldenberg
Journal:  J Am Coll Cardiol       Date:  2021-05-25       Impact factor: 27.203

7.  Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study.

Authors:  Pier D Lambiase; Dominic A Theuns; Francis Murgatroyd; Craig Barr; Lars Eckardt; Petr Neuzil; Marcoen Scholten; Margaret Hood; Jȕrgen Kuschyk; Amy J Brisben; Nathan Carter; Timothy M Stivland; Reinoud Knops; Lucas V A Boersma
Journal:  Eur Heart J       Date:  2022-06-01       Impact factor: 35.855

8.  Outcomes Following Standardized Implantable Cardioverter-defibrillator Reprogramming.

Authors:  Matthew Martini; Matthew Kalscheur; Erin Dehn; Teri McSherry; Miguel Leal; Aimee Broman; Ryan Kipp
Journal:  J Innov Card Rhythm Manag       Date:  2022-04-15

Review 9.  Assessing Candidacy for Primary Preventative Implantable Cardioverter-defibrillators in Pediatric Patients with Ion Channelopathies: Weighing the Risks and Benefits.

Authors:  Madeline L Townsend; Peter F Aziz
Journal:  J Innov Card Rhythm Manag       Date:  2018-09-15

Review 10.  Psychological Issues in Managing Families with Inherited Cardiovascular Diseases.

Authors:  Jodie Ingles
Journal:  Cold Spring Harb Perspect Med       Date:  2020-09-01       Impact factor: 5.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.